Regeneron, a Leading U.S. Biotechnology Company, to Acquire 23andMe for $2.56 Billion
The biotechnology industry in the United States is witnessing a major strategic move as Regeneron Pharmaceuticals, one of the country’s most respected biotech companies, moves forward with the acquisition of 23andMe for $256 million. This development has attracted strong attention from investors, healthcare experts, and technology enthusiasts, as it brings together two powerful forces: advanced … Read more